Xilio Therapeutics provides pipeline updates

Xilio Therapeutics has issued updates on its pipeline and business operations, alongside its fourth quarter and full-year 2025 financial results. The company's lead candidate, XTX501, a bispecific PD-1 / masked IL-2 therapy, is progressing as planned. An Investigational New Drug (IND) submission is anticipated in mid-2026, with Phase 1 clinical trials expected to commence in the latter half of the year. These developments signal continued progress in Xilio's therapeutic development efforts.